Olimel N12 (Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin)

Olimel N12 provides nutritional amino acid support for conditions where protein synthesis is compromised.

• Post‑operative recovery: helps meet increased protein needs during healing.
• Severe trauma or burns: supports tissue repair and nitrogen balance.
• Critical illness or intensive care: contributes to maintaining lean body mass in patients receiving total parenteral nutrition.
• Chronic renal failure on dialysis: supplies essential amino acids while limiting nitrogen waste.
• Malnutrition in oncology patients: assists in preserving muscle mass during chemotherapy.
• Liver disease‑related catabolism: provides balanced amino acids for patients with hepatic insufficiency.

• Olimel N12 supplies a balanced profile of essential and non‑essential amino acids directly into the bloodstream, bypassing gastrointestinal absorption. The amino acids become substrates for protein synthesis, support nitrogen balance, and aid in the production of neurotransmitters and metabolic intermediates, thereby contributing to tissue repair and metabolic stability in patients unable to obtain adequate nutrition orally.

Adverse reactions are reported infrequently but may occur with any intravenous amino acid formulation.

Common Side Effects

• Mild fever or chills: transient rise in body temperature after infusion.
• Local irritation: redness or discomfort at the infusion site.
• Nausea: occasional feeling of queasiness during or after administration.
• Headache: mild headache reported by some patients.
• Elevated serum electrolytes: temporary changes in potassium or phosphate levels.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical intervention.
• Hyperammonemia: excessive ammonia accumulation leading to neurological symptoms.
• Metabolic acidosis: significant shift in blood pH requiring correction.
• Thrombophlebitis: inflammation of a vein with clot formation at the infusion site.
• Renal dysfunction: worsening kidney function in susceptible individuals.

When administering Olimel N12, clinicians should consider patient‑specific factors and follow best practice guidelines.

• Assess renal function: adjust infusion rate in patients with impaired kidneys.
• Monitor electrolytes: check serum potassium, phosphate and calcium during therapy.
• Evaluate liver function: watch for signs of hyperammonemia.
• Observe for allergic reactions: be prepared to manage anaphylaxis.
• Use aseptic technique: maintain sterility to prevent contamination.
• Store at 2-8°C: keep refrigerated, protect from light and do not freeze the vial or powder.

Olimel N12 may interact with other intravenous solutions and medications administered concurrently.

Major Interactions (Avoid)

• High‑dose potassium chloride: risk of hyperkalemia when combined with amino acid solutions.
• Acidic IV fluids: may cause precipitation of calcium salts in the mixture.

Moderate Interactions (Monitor Closely)

• Loop diuretics: can amplify electrolyte shifts, requiring closer monitoring.
• Anticoagulants: altered plasma protein binding may affect drug levels.
• Insulin therapy: amino acids stimulate insulin release, potentially affecting glucose control.
• Hepatotoxic drugs: increased risk of hyperammonemia when combined with liver‑targeting agents.
• Other parenteral nutrition ​​  ​  ​   ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​